MedAxiom Announces Industry Partnership With Caristo Diagnostics
MedAxiom, the cardiovascular community’s premier source for organizational performance solutions, is excited to announce an industry partnership with Caristo Diagnostics, developer of a new artificial intelligence (AI)-powered heart disease detection solution allowing healthcare providers to identify hidden heart attack risks before symptoms appear.
“We are thrilled to partner with an innovative company like Caristo who brings new solutions to the MedAxiom community by leveraging emerging technology. Caristo’s innovative approach of analyzing inflammation using the Fat Attenuation Index is novel in the cardiovascular realm. Caristo also stands out as one of five companies selected to join the 2024 HeartX cohort, and we are looking forward to partnering with Caristo to educate the MedAxiom community in 2025 and beyond,” said Joe Sasson, PhD, MedAxiom’s executive vice president of Ventures and chief commercial officer.
Caristo’s AI-powered inflammation and plaque analysis technology is designed to save lives through early detection and personalized prevention of coronary artery disease (CAD). Their CaRi-Heart® solution visualizes and quantifies hidden coronary inflammation on routine coronary CT scans, a key driver of CAD. Its novel imaging biomarker, the Fat Attenuation Index Score (FAI-Score™), predicts a patient’s risk of cardiac mortality up to 10 years in advance, enabling clinicians to diagnose early stages of coronary disease and allowing for earlier intervention and treatment. * Furthermore, Caristo’s Food and Drug Administration (FDA)-cleared CaRi-Plaque™ technology determines the presence, extent and severity of coronary plaques and luminal stenosis to provide critical insights into coronary anatomy and plaque pathology. .
“Caristo is excited to enter the U.S. market after recently receiving FDA clearance for our CaRi-Plaque technology. Our partnership with MedAxiom and their invaluable network will accelerate our expansion into the U.S. market as we prepare to revolutionize cardiac care and improve patient outcomes,” Frank Cheng, Caristo Diagnostics chief executive officer.
* The CaRi-Heart software is regulatory cleared for use in the UK and EU and is currently available for research use only in the U.S.
About MedAxiom
MedAxiom, an American College of Cardiology Company, is the cardiovascular community’s premier source for organizational performance solutions. MedAxiom is transforming cardiovascular care by combining the knowledge and power of hundreds of cardiovascular organization members, thousands of administrators, clinicians and revenue cycle experts, and dozens of industry partners. Through the delivery of proprietary tools, smart data and proven strategies, MedAxiom helps cardiovascular organizations achieve the Quadruple Aim of better outcomes, lower costs, improved patient experience and improved clinician experience. For more information, visit medaxiom.com.
###
